InspireMD (NSPR)
NASDAQ:NSPR
Want to see NSPR full AI Analyst Report?
NSPR Stock Chart & Stats
$1.84
$0.06(2.18%)
At close: 4:00 PM EST
$1.84
$0.06(2.18%)
Day’s Range― - ―
52-Week Range$0.86 - $2.93
Previous CloseN/A
Volume8.46K
Average Volume (3M)102.59K
Market Cap
$42.16M
Enterprise Value$33.80M
Total Cash (Recent Filing)$41.57M
Total Debt (Recent Filing)$2.04M
Price to Earnings (P/E)―
Beta-0.32
Next Earnings
Aug 11, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding46,838,963
10 Day Avg. Volume68,719
30 Day Avg. Volume102,589
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.37
Price to Sales (P/S)14.56
P/FCF Ratio-3.56
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue3.12
Enterprise Value/Gross Profit11.11
Enterprise Value/Ebitda-0.66
Forecast
1Y Price Target
$3.67Price Target Upside99.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.74
Revenue Forecast (FY)$12.49M
Bulls Say, Bears Say
Bulls Say
Clinical Safety And EfficacyClinical trial results showing very low rates of major complications support the device's safety profile versus existing treatments and could increase clinician confidence.
Innovative Device DesignProprietary MicroNet mesh that traps plaque and reduces embolization offers a distinct clinical advantage and could encourage a shift toward a stent-first treatment approach.
Regulatory Approval And Commercial LaunchFDA premarket approval and an established US commercial launch create a clear pathway for US sales and broader physician adoption.
Bears Say
Commercial Adoption And Procedure VolumeA small number of procedures performed to date signals limited commercial uptake, which could slow revenue growth and delay broader market penetration.
Financial Condition And Funding RiskOngoing GAAP losses and persistent cash burn raise the possibility that additional capital may be required if commercial momentum does not improve.
InspireMD News
NSPR FAQ
What was InspireMD’s price range in the past 12 months?
InspireMD lowest stock price was $0.86 and its highest was $2.93 in the past 12 months.
What is InspireMD’s market cap?
InspireMD’s market cap is $42.16M.
When is InspireMD’s upcoming earnings report date?
InspireMD’s upcoming earnings report date is Aug 11, 2026 which is in 72 days.
How were InspireMD’s earnings last quarter?
InspireMD released its earnings results on May 04, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.02.
Is InspireMD overvalued?
According to Wall Street analysts InspireMD’s price is currently Undervalued.
Does InspireMD pay dividends?
InspireMD does not currently pay dividends.
What is InspireMD’s EPS estimate?
InspireMD’s EPS estimate is -0.2.
How many shares outstanding does InspireMD have?
InspireMD has 46,838,963 shares outstanding.
What happened to InspireMD’s price movement after its last earnings report?
InspireMD reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went down -5.983%.
Which hedge fund is a major shareholder of InspireMD?
Currently, no hedge funds are holding shares in NSPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InspireMD Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.67 (99.28% Upside)
$3.67 (99.28% Upside)
Insider Transactions
Bought Shares
Worth $176.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.82%
12-Months-Change
Fundamentals
Return on Equity
-81.52%
Trailing 12-Months
Asset Growth
46.03%
Trailing 12-Months
Company Description
InspireMD
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
NSPR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: strong commercial traction and substantial year-over-year revenue growth (122%), expanding international sales (48% YoY), a large clinical installed base (>70,000 cases), and clear regulatory/clinical pathways (C-GUARDIANS III initiation, expected approvals). Offsetting these positives is a material near-term operational setback — a voluntary U.S. pause/recall of the CGuard Prime 135 delivery system — which led to impairment charges, planned reserves (~$1.35M combined), withdrawal of 2026 revenue guidance, increased operating expenses, and reduced cash versus year-end. Management characterizes the issue as technical (not implant safety), has identified root causes, and expects a path to remediation and relaunch, but timing is uncertain. Overall, the call balances strong growth and long-term opportunity with a meaningful short-term commercial disruption and financial impact.View all NSPR earnings summariesNSPR Stock 12 Month Forecast
Average Price Target
$3.67
▲(99.28% Upside)
Technical Analysis
Anika Therapeutics
―
Apyx Medical
―
EDAP TMS
―
Vivani Medical
―
Xtant Medical Holdings
―
Ownership Overview
21.29% Insiders
0.04% Mutual Funds
36.98% Other Institutional Investors
41.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---